Get the Stockscreener App
130.14
2.63%
3.33
Pre-market:
130.86
0.72
+0.55%
Glaukos Corp stock is traded at $130.14, with a volume of 801.88K.
It is up +2.63% in the last 24 hours and down -9.63% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$126.81
Open:
$128.58
24h Volume:
801.88K
Relative Volume:
0.87
Market Cap:
$7.64B
Revenue:
$551.35M
Net Income/Loss:
$-189.33M
P/E Ratio:
-39.54
EPS:
-3.2916
Net Cash Flow:
$-35.09M
1W Performance:
+6.71%
1M Performance:
-9.63%
6M Performance:
+16.48%
1Y Performance:
+33.34%
1-Day Range:
$127.83
$130.67
1-Week Range:
$119.66
$130.67
52-Week Range:
$73.16
$148.11
Glaukos Corp Stock (GKOS) Company Profile
Name
Glaukos Corp
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
130.14 | 7.64B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corp Stock (GKOS) Latest News
GKOS Maintained by Citigroup -- Price Target Raised to $162 - GuruFocus
Clearbridge Investments LLC Lowers Stake in Glaukos Corporation $GKOS - MarketBeat
GKOS Reiterated by BTIG -- Price Target Maintained at $162 - GuruFocus
Stifel reiterates Glaukos stock rating on regulatory optimism By Investing.com - Investing.com South Africa
Stifel reiterates Glaukos stock rating on regulatory optimism - Investing.com
Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus - AD HOC NEWS
Why Is NYSE Composite Watching Glaukos’ iDose TR Adoption Momentum? - Kalkine Media
Midday Stock Roundup: Alignment Healthcare Surges - Orange County Business Journal
A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE), Dexcom (DXCM) and Glaukos (GKOS) - The Globe and Mail
Glaukos Corp Balance Sheet – XETR:6GJ - TradingView
Glaukos Corp Statistics – XETR:6GJ - TradingView
Glaukos Corp Cash Flow – XETR:6GJ - TradingView
Glaukos Corp Revenue Breakdown – XETR:6GJ - TradingView
Glaukos Corp stock (US3773221029): shares near recent highs as valuation comes into focus - AD HOC NEWS
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Yahoo Finance
Glaukos (NYSE: GKOS) investors approve board slate, pay and Ernst & Young - Stock Titan
Glaukos Corp. Hits Day High with Strong 7.43% Intraday Surge - Markets Mojo
Glaukos (GKOS) director Leana Wen granted RSUs and options in 2026 - Stock Titan
Glaukos (NYSE: GKOS) director granted new RSUs and stock options - Stock Titan
Glaukos (GKOS) director Denice Torres granted RSUs and stock options - Stock Titan
Glaukos (GKOS) director Mark Foley receives new RSUs and stock options - Stock Titan
GLAUKOS (GKOS) director David Hoffmeister receives new RSU and option grants - Stock Titan
Glaukos Corp (GKOS) director Kliman receives new RSU and option awards - Stock Titan
Director at Glaukos (NYSE: GKOS) granted new stock units and options - Stock Titan
EBITDA per share of Glaukos Corp – FWB:6GJ - TradingView
Glaukos Corp stock (US3773221029): shares active on NYSE as market watches next catalysts - AD HOC NEWS
Glaukos (GKOS) director exercises 15,000 options at $24.69 - Stock Titan
Goldman Sachs Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153 - Moomoo
Glaukos Corp. Stock Hits Day Low of $118.64 Amid Price Pressure - Markets Mojo
Glaukos (GKOS) Faces Selling Pressure Amid iDose Procedure Conce - GuruFocus
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
BTIG raises Glaukos stock price target to $162 on product pipeline - Investing.com
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Glaukos Corp stock (US3773221029): 52-week high and fresh insider sale stir investor interest - AD HOC NEWS
Glaukos director Kliman sells $703,800 in stock - Investing.com
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at $146.90 - Investing.com UK
Glaukos (GKOS) price target increased by 12.59% to 154.96 - MSN
DNB Asset Management AS Grows Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):